+44 (0) 20 7549 9987 | USA callers: +1 212 220 8419

Contact Us Now

“Top 25 Vaccines market set to grow to $41bn by 2024” says new Visiongain report

20 June 2019
Pharma

Visiongain has launched a new pharma report Top 25 Vaccines Market Forecast 2019-2029: Prevnar/Prevnar 13, Gardasil/Gardasil 9, Fluzone/Vaxigrip, Pentacel, Infanrix, Pediarix, GSK Hepatitis Vaccine, Pneumovax 23, Varivax, Bexsero, Boostrix, Menactra, RotaTeq, Rotarix, Zostavax, Synflorix, FluLaval/Fluarix, ProQuad, M-M-R II, Adacel, Menveo, Repevax, Cervarix, FSME/IMMUN-TicoVac, Ixiaro, FluMist/Fluenz.

Visiongain predicts that the overall global market, submarket and product revenues will continue to grow, with human vaccines driving the sales of pharmaceutical companies. The industry will see entry of new key players and advancements in technology, overall resulting in an increase in market size of the world human vaccines market.

The lead analyst of the report commented "There is an increasing focus to identify diseases that currently do not have a vaccine. This breeds a strong platform for both start-ups and larger pharmaceutical companies to create new vaccines that are not already on the market. This prevents stagnation within the market and will help drive the growth of the human vaccines market.

The media is playing an increasingly important role in spreading awareness about the complications of various infectious diseases if the public is not immunized. The increasing levels of awareness has promoted the benefits of vaccines as the most effective form of immunization against infection, consequently leading to increased demand for the vaccines."

Leading companies featured in the report include AstraZeneca, Eli Lilly, Emergent BioSolutions Inc., GlaxoSmithKline, Johnson & Johnson, Merck & Co., Pfizer, Sanofi, Serum Institute of India Private Limited, Takeda and other companies.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Drug Delivery Technologies Market Report 2024-2034

The global Drug Delivery Technologies market is estimated at US$1,729.6 billion in 2024 and is projected to grow at a CAGR of 5.5% during the forecast period 2024-2034.

23 April 2024

Read

Visiongain Publishes Cell Therapy Technologies Market Report 2024-2034

The cell therapy technologies market is estimated at US$7,041.3 million in 2024 and is projected to grow at a CAGR of 10.7% during the forecast period 2024-2034.

18 April 2024

Read

Visiongain Publishes Automation in Biopharma Industry Market Report 2024-2034

The global Automation in Biopharma Industry market is estimated at US$1,954.3 million in 2024 and is projected to grow at a CAGR of 7% during the forecast period 2024-2034.

17 April 2024

Read

Visiongain Publishes Anti-obesity Drugs Market Report 2024-2034

The global Anti-obesity Drugs market is estimated at US$11,540.2 million in 2024 and is expected to register a CAGR of 21.2% from 2024 to 2034.

12 April 2024

Read